K. Rasor

Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.

Dolores Diaz, Jianping Yin, Michael Burkard, 2016, Journal of medicinal chemistry.

Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-Raf(V600E) kinase.

E. Laird, S. Gloor, G. Vigers, 2014, Bioorganic & medicinal chemistry letters.

The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase.

Tyler T. Risom, E. Laird, S. Gloor, 2012, Bioorganic & medicinal chemistry letters.

Abstract A252: A phase 1 study of ARRY-382, an oral inhibitor of colony-stimulating factor-1 receptor (CSF1R), in patients with advanced or metastatic cancers.

Suzanne F. Jones, A. Tolcher, K. Wood, 2013 .

Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2.

J. Blake, Jianping Yin, Weiru Wang, 2015, Journal of medicinal chemistry.

Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.

E. Laird, S. Gloor, Jonas Grina, 2012, Bioorganic & medicinal chemistry letters.

Abstract DDT02-03: Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development

S. Gould, M. Belvin, Peter Yin, 2014 .

Preliminary safety and efficacy of ATA188, a pre-manufactured, unrelated donor (off-the-shelf, allogeneic) Epstein-Barr virus-targeted T-cell immunotherapy for patients with progressive forms of multiple sclerosis

S. Broadley, P. Foubert, M. Pender, 2019 .